This guide covers: How GLP-1 medications work and why their effects extend beyond glucose Blood sugar control: what results to expect Weight loss: magnitude and timeline Cardiovascular benefits: the evidence and what it means Kidney and liver protection Comparing different GLP-1 medications (semaglutide, tirzepatide, liraglutide, dulaglutide) How GLP-1s fit with other diabetes treatments Who benefits most from these medications Practical considerations for access and cost Key Takeaways GLP-1 medications produce comprehensive metabolic improvement , addressing blood sugar, weight, cardiovascular risk, and organ health simultaneously HbA1c reductions average 1.0-2.0 percentage points , with many patients achieving target levels under 7% Weight loss averages 10-15% with semaglutide , substantially more than older diabetes medications Cardiovascular event reduction of 20% has been demonstrated in high-risk patients, making GLP-1s the preferred choice for patients with heart disease Kidney protection extends beyond what glucose control alone would provide Tirzepatide (dual GLP-1/GIP agonist) produces greater improvements than single-mechanism GLP-1 agonists These medications can reduce or eliminate the need for other diabetes drugs , including insulin in many cases Side effects are primarily gastrointestinal and usually improve with time and proper titration Cost remains a barrier , though compounded options and manufacturer programs improve access GLP-1 medications are now recommended as first-line treatment for many Type 2 diabetes patients, particularly those with cardiovascular disease or obesity Understanding GLP-1 Medications Before exploring their benefits, understanding how these medications work explains why they affect so many aspects of metabolic health
Clinical studies of oral insulin, calcitonin, and other peptides consistently showed marked reductions or unpredictable changes in exposure when administered with food, necessitating strict fasting requirements that proved impractical for chronic therapy ( 4.2 Two classes of variability accommodation: why the distinction matters Not all variability is equally consequential
According to the World Health Organization, mutant enzymes have been classified into five classes in the order of descending severity [43]
The trial had a median follow-up of 3.4 years
Participating NRAs are TGA, FDA, Health Canada, HSA, Swissmedic, ANVISA (Brazil), MHRA and Israel
